Analyzing R&D Budgets: Dr. Reddy's Laboratories Limited vs Evotec SE

R&D Spending: Dr. Reddy's vs. Evotec

__timestampDr. Reddy's Laboratories LimitedEvotec SE
Wednesday, January 1, 20141240200000012404000
Thursday, January 1, 20151744900000018343000
Friday, January 1, 20161783400000018108000
Sunday, January 1, 20171955100000017614000
Monday, January 1, 20181826500000035619000
Tuesday, January 1, 20191560700000058432000
Wednesday, January 1, 20201541000000063945000
Friday, January 1, 20211654100000072200000
Saturday, January 1, 20221748200000076642000
Sunday, January 1, 20231938100000057519000
Monday, January 1, 202422873000000
Loading chart...

Unleashing insights

A Decade of Innovation: R&D Spending Trends

In the ever-evolving landscape of pharmaceuticals and biotechnology, research and development (R&D) spending is a critical indicator of innovation and future growth. Over the past decade, Dr. Reddy's Laboratories Limited has consistently outpaced Evotec SE in R&D investments. From 2014 to 2023, Dr. Reddy's Laboratories increased its R&D budget by approximately 85%, peaking in 2024 with a remarkable 2.3 trillion. In contrast, Evotec SE's R&D spending grew by over 500% from 2014 to 2022, highlighting its commitment to innovation despite a smaller budget.

The data reveals a strategic focus on R&D by both companies, albeit at different scales. Dr. Reddy's Laboratories' substantial investments underscore its ambition to lead in the pharmaceutical sector, while Evotec SE's growth trajectory reflects its dynamic approach in the biotech industry. Missing data for 2024 suggests ongoing developments worth watching.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025